Senior Director, Clinical Pharmacology
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company
| Company | Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company |
| Category | Healthcare |
| Location | Boston |
| Remote | On-site (inferred) |
| Employment | Not stated |
| Level | Director |
| Salary | Not stated by the employer |
| Posted | 21 Apr 2026 |
| Last verified | 13 Aug 2026 |
| Source | Employer ATS (greenhouse) |
Description
Description of Role
Centessa is seeking an experienced Senior Director, Clinical Pharmacology (translational) to provide scientific and strategic leadership for translational clinical pharmacology across a diverse pipeline spanning early development through late‑stage and registrational programs. Reporting to the Executive Director, Clinical Pharmacology, this position is accountable for developing and executing clinical pharmacology strategies that address the unique challenges of neuroscience drug development, including CNS exposure, dose optimization, and translational relevance. The Senior Director partners closely with cross‑functional teams, and cross-program teams to achieve broader translational understanding of our assets, and application of that knowledge to development programs. Additionally, they will represent clinical pharmacology in regulatory interactions to enable efficient, data‑driven advancement of therapies across our neuroscience portfolio.
Key Responsibilities
Lead strategy for collection and interpretation of information across in vitro, in vivo, literature of competitive sources, and clinical data to develop a translational knowledge base to Centessa assets
Drive dose selection and optimization by integrating PK, PD, safety, efficacy, and CNS‑specific biomarkers
Lead model‑informed drug development, including population PK, PK/PD, and exposure–response analyses relevant to CNS targets and clinical safety
Assess and guide strategies for CNS exposure, brain penetration, target engagement, and translational biomarkers
Lead clinical pharmacology strategy for CNS and neuroscience programs from first‑in‑human through registrational and post‑marketing stages
Design, execute, and interpret clinical pharmacology studies, including FIH, multiple‑ascending dose, DDI, biopharmaceutics, and patient studies
Serve as the clinical pharmacology lead on program teams, clinical sub‑teams, and trial working groups
Author and oversee clinical pharmacology sections of regulatory documents (e.g., INDs, CTAs, IBs, NDAs)
Represent clinical pharmacology in interactions with FDA and other global health authorities, supporting dose justification and labeling discussions
Partner closely with DMPK, Translational Sciences, Clinical Development, Biomarkers, Biostatistics, CMC, and Regulatory Affairs
Oversee CROs and external vendors conducting clinical pharmacology and modeling activities
Ensure timely communication and clear interpretation of clinical pharmacology results to internal stakeholders
Contribute to portfolio strategy, program prioritization, risk mitigation, and long‑range clinical development planning for CNS assets
Serve as a subject‑matter expert on clinical pharmacology
Mentor and develop clinical pharmacology talent as the pipeline and organization grow
Ensure high‑quality, submission‑ready documentation aligned with global regulatory standards
Qualifications
PhD, PharmD, or MD in Clinical Pharmacology, Pharmacokinetics, Pharmaceutical Sciences, or a related discipline
8–12+ years of experience in clinical pharmacology within biopharma, with demonstrated impact in translational science in drug development
Strong expertise in PK, PD, PK/PD integration, exposure–response analyses, and drug–drug interaction assessment
Extensive experience developing and executing clinical pharmacology strategies for early‑ through late‑stage programs, including registrat